<DOC>
	<DOCNO>NCT00945880</DOCNO>
	<brief_summary>The purpose study test hypothesis clemizole hydrochloride safe well tolerate administer subject infect hepatitis C virus yet receive treatment . This study also examine virus body respond clemizole hydrochloride .</brief_summary>
	<brief_title>Safety Tolerability Study Clemizole Hydrochloride Treat Hepatitis C Subjects Who Are Treatment-Naive</brief_title>
	<detailed_description>This study phase 1b , open label study four week treatment 100 mg po BID clemizole hydrochloride administer immediately prior initiation treatment HCV standard care therapy consist pegylated interferon ribavirin treatment-naïve subject chronically infect HCV genotype 1 genotype 2 . The duration study subject approximately 11 week ( three week screen period , four week treatment period four week safety follow-up period ) . The duration entire study anticipate approximately four month ( first subject last subject ) . Pharmacokinetic sample do Day 1 Day 28 dosing . PK sample conduct subject consent participate PK portion study . Participation PK sample optional subject .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Males female , 18 55 year age diagnose HCV PCR HCV treatmentnaïve patient already commit undergo standard care therapy ( SOC ) HCV ( pegylated interferon ribavirin ) , wish participate study immediately prior initiation SOC Chronic hepatitis C infection , genotype 1 genotype 2 , two documented test ( PCR HCV Ab ; one test HCV Ab , second test must PCR PCR test must least 6 month HCV Ab test ) least 6 month apart Liver biopsy within last two ( 2 ) year ( biopsy do Screening Visit ) Positive viral load &lt; 1,000,000 IU/mL measure quantitative PCR Electrocardiogram ( ECG ) show acute ischemia clinically significant abnormality QT/QTc interval &lt; 450 millisecond use Bazett 's correction : QTc =QT/RR0.5 ( ICH Guidance E14 Clinical Evaluation QT/QTc Interval Prolongation Proarrhythmic Potential NonAntiarrhythmic Drugs ) Females childbearing potential ( intact uterus within 1 year since last menstrual period ) nonlactating negative serum pregnancy test . In addition , subject agree use one follow acceptable birth control method throughout study : 1. abstinence 2. surgical sterilization ( bilateral tubal ligation , hysterectomy , bilateral oophorectomy ) six month minimum 3 . IUD place least six month 4. barrier method ( condom diaphragm ) spermicide 5. surgical sterilization partner ( vasectomy six month ) 6. hormonal contraceptive least three month prior first dose study drug Willing able comply study procedure provide write informed consent Participation clinical trial use investigational agent within 30 day Study Visit 1 Patients coinfected HIV Patients screen test positive HBsAg , antiHIV Ab Liver biopsy within last 2 year show Stage III fibrosis high Clinical evidence suspicion cirrhosis Active jaundice define total bilirubin &gt; 2.0 INR ≥ 1.5 Eating disorder alcohol abuse within past 2 year , excessive alcohol intake ( &gt; 20 g per day female ( 1.5 standard alcohol drink ) &gt; 30 g per day male ( 2.0 standard alcohol drink ) ( standard drink contain 14 g alcohol : 12 oz beer , 5 oz wine 1.5 oz spirit ) ( 1.0 fluid oz ( US ) = 29.57 ml ) , opinion investigator , alcohol use pattern interfere study conduct Drug abuse within last six month exception cannabinoids derivatives Patients absolute neutrophil count ( ANC ) &lt; 1500 cells/mm3 ; platelet count &lt; 135,000 cells/mm3 ; hemoglobin &lt; 12 g/dL woman &lt; 13 g/dL men ; abnormal TSH , T4 , T3or thyroid function adequately control ; serum creatinine concentration ≥1.5 time upper limit normal ( ULN ) History clinical evidence follow : 1. variceal bleeding , ascites , hepatic encephalopathy , CTP score &gt; 6 , decompensated liver disease form nonviral hepatitis 2. immunologically mediate disease ( e.g. , rheumatoid arthritis , inflammatory bowel disease , severe psoriasis , systemic lupus erythematosus ) require intermittent nonsteroidal antiinflammatory medication management require frequent prolong use corticosteroid ( inhaled asthma medication allow ) 3. malignancy within 3 year except basal cell skin cancer 4. significant unstable cardiac disease ( e.g. , angina , congestive heart failure , uncontrolled hypertension , history arrhythmia ) 5. chronic pulmonary disease ( e.g. , chronic obstructive pulmonary disease ) associate functional impairment 6. severe uncontrolled psychiatric disease , include severe depression , history suicidal ideation , suicidal attempt psychosis require medication and/or hospitalization Patients body mass index &gt; 30 kg/m2 Concomitant drug know prolong QT interval ( see Appendix E ) Concomitant use immunosuppressive immune modulate agent Patients serious condition , opinion investigator , would preclude evaluation response make unlikely contemplated course therapy followup could complete increase risk subject participation trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>HCV</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Hepatitis</keyword>
</DOC>